Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
PERIOSTINE
1 other identifier
interventional
65
1 country
1
Brief Summary
Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2016
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 25, 2016
CompletedFirst Submitted
Initial submission to the registry
August 11, 2016
CompletedFirst Posted
Study publicly available on registry
August 16, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 10, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2018
CompletedDecember 19, 2025
December 1, 2025
1.9 years
August 11, 2016
December 13, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Periostin rate in serum
At inclusion
Secondary Outcomes (3)
Periostin rate in serum according to the number of fibrotic bones
At inclusion
Periostin rate in serum in patients with severe phenotype of the disease
At inclusion
Periostin rate in serum in patients with Mac Cune Albright syndrome
At inclusion
Study Arms (2)
Patients with bone fibrous dysplasia
EXPERIMENTALPatients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
Control subjects
NO INTERVENTIONControl subjects will have no intervention
Interventions
Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
Eligibility Criteria
You may qualify if:
- patients with fibrous dysplasia of the bone
- access to social security
- informed consent
You may not qualify if:
- no informed consent
- pregnancy
- patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service de rhumatologie Pavillon F - Hôpital Edouard Herriot
Lyon, 69437, France
Related Publications (1)
Guerin Lemaire H, Merle B, Borel O, Gensburger D, Chapurlat R. Serum periostin levels and severity of fibrous dysplasia of bone. Bone. 2019 Apr;121:68-71. doi: 10.1016/j.bone.2019.01.004. Epub 2019 Jan 4.
PMID: 30616028RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 11, 2016
First Posted
August 16, 2016
Study Start
May 25, 2016
Primary Completion
April 10, 2018
Study Completion
April 10, 2018
Last Updated
December 19, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share